default author photo

Fabian Zohren

Pfizer Oncology

235 East 42 Street

New York, NY 10017

United States

SCHOLARLY PAPERS

1

DOWNLOADS

101

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study

Number of pages: 52 Posted: 28 Oct 2020
ARCAGY-GINECO, Saitama Medical University International Medical Center (SIMC), University College London - UCL Cancer Institute, University of Toronto - Princess Margaret Cancer Centre, University College London - UCL Cancer Institute, University of Claude Bernard Lyon 1 - Medical Oncology Department, Cabrini Hospital - Department of Medical Oncology, Ospedale San Giovanni - Oncology Institute of Southern Switzerland (IOSI), National Cancer Center Hospital - Department of Breast and Medical Oncology, Government of the United Kingdom - Royal Marsden NHS Foundation Trust, Université Paris XI Sud - Gustave Roussy Cancer Campus, BC Cancer, University of Ulsan - Department of Oncology, Poznan University of Medical Sciences - Department of Oncology, National Cancer Center - Center for Uterine CancerNational Cancer Center, Korea - Center for Gynecologic Cancer, Willamette Valley Cancer Institute and Research Center, Pfizer Oncology, Pfizer Oncology, Pfizer, Inc. - Pfizer Global Biometrics and Data Management, Pfizer Oncology and University of Arizona - College of Medicine, Arizona Oncology (US Oncology Network)
Downloads 101 (684,672)

Abstract:

Loading...

ovarian cancer, Avelumab, PD-L1, Phase 3, immune checkpoint inhibitor